Alumis
NASDAQ: ALMSSouth San Francisco, US · Founded 2021 · 262 employees on LinkedIn · 8 known investors
Find your way into Alumis
15 people in our graph share verified history with the Alumis team — schools, employers, funds. One of them is your warm intro.
Pamela Kleinunlockedknows Martin Babler · together at Sardona Therapeutics (overlapped)
×4knows the team · via Principia Biopharma
knows the team · via Alumis
×4knows the team · via Sardona Therapeutics
knows the team · via Neoleukin Therapeutics
knows the team · via Prelude Therapeutics
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Founders & leadership
MB
Martin BablerinPresident, Chief Executive Officer and Chairman of the BoardHe has served on the boards of Prelude Therapeutics since 2021, 89bio from 2024 to 2025, and as chairman of the board of Sardona Therapeutics from 2021 to 2025. He has also been a co-owner of Paradigm Ranch Management LLC since 2008.
MB
Mark BradleyinChief Development Officer
KB
Kolbot ByinSVP, Head of Technical Operations
JD
Jack DanilkowiczinChief Commercial Officer
JD
Jörn DrappainChief Medical Officer
DM
David M GoldsteininChief Scientific Officer
GH
Grace HaltehinSVP, Head of Quality and Regulatory
RH
Roy HardimaninChief Business and Strategy Officer
CL
Claire LangrishinSVP, Head of Immunology and Translational Science
SP
Sanam PangaliChief Legal Officer and Corporate Secretary
JS
John SchroerinChief Financial Officer
Investors · 8
Funding
SEC filings, press & company announcements- Undisclosed amountpublic offeringJan 2026 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 2
by search overlap
Exelixis129 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
IQVIA110 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Companies competing with Alumis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Alumis posts $235M loss, holds $502M in cash | ALMS Quarterly Report (10-Q)stocktitan.net · Aug 2026Frequently asked questions
- What does Alumis do?
- Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
- Who are Alumis's investors?
- Alumis's investors include Foresite Capital, Nextech Invest, OrbiMed, Samsara BioCapital, SR One Capital Management, venBio Partners, Westlake Village BioPartners, venBio Global Strategic.
- Where is Alumis headquartered?
- Alumis is headquartered in South San Francisco, US.